One plan - full access

No subscription, no auto-renewal, no hidden terms.
Pay once and use it for 30 days.

PRO plan No auto-renewal
$18

30 days of full access
One-time payment

🌐 US & Global Companies
Get access for 30 days →
♧ Secure payment · Instant access

What is included

  • ✓Full access to detailed company analysis
  • ✓Fundamental screener
  • ✓Advanced stock screener filters
  • ✓5 ratings. Separate lists for US & Global Companies and MOEX
  • ✓Company data export in XLSX and CSV
  • ✓MarketCap’s overall ranking of top companies
  • ✓Analytics updates after each new financial report
⚠ The service is not an investment advisor. Financial statement data from public companies is available to everyone - MarketCap structures and analyzes it.
Immatics N.V. logo
Immatics N.V. IMTX
$ 6.42 -0.47%
report update icon

Quarterly report 2025-Q4
added 05-12-2026

Immatics N.V. Financial Statements 2025-2011 | IMTX

Annual Financial Statements Immatics N.V.

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

735 M 1.28 B 815 M 508 M 503 M - 192 M 176 M - - - - - - -

Shares

122 M 106 M 80.5 M 67.2 M 62.9 M - 18 M 18 M - - - - - - -

Historical Prices

6.01 12.1 10.1 7.55 8 10.8 10.7 9.75 - - - - - - -

Net Income

-196 M 15.2 M -94.6 M 27.7 M -93.3 M - - - - - - - - - -

Operating Income

-182 M -38.6 M -102 M 30 M -86.3 M -69.7 M -33 M -34.4 M - - - - - - -

Interest Expense

946 K 886 K 831 K 1.04 M - - - - - - - - - - -

EBITDA

-182 M -38.6 M -102 M 30 M -86.3 M - - - - - - - - - -

General and Administrative Expenses

51.2 M 46.4 M 38.2 M 36.1 M 33.8 M - - - - - - - - - -

All numbers in EUR currency

Quarterly Income Statement Immatics N.V.

2025-Q4 2025-Q2 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q2 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

122 M 122 M 106 M 103 M 103 M 98.7 M 80.5 M 77.3 M - - - - - - 62.9 M - - - 33.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Net Income

-196 M -70.3 M 15.2 M -5.3 M -18 M -2.24 M -94.6 M -24.6 M - - - - - - -26.5 M - - - -21.3 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-182 M -53.1 M -38.6 M - -26.6 M - -102 M -14.3 M - - - - - - -23.4 M - - - -19.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Interest Expense

946 K 244 K 886 K - 226 K - 831 K 206 K - - - - - - 140 K - - - 81 K - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

EBITDA

-182 M -53.1 M -38.6 M - -26.6 M - -102 M -14.3 M - - - - - - -23.4 M - - - -19.6 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

General and Administrative Expenses

51.2 M 12.8 M 46.4 M - 10.1 M - 38.2 M 9.36 M - - - - - - 8.27 M - - - 10.1 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

All numbers in EUR currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements Immatics N.V. IMTX
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting Immatics N.V. plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Mustang Bio Mustang Bio
MBIO
$ 0.44 12.95 % $ 2.16 M usaUSA
Cerevel Therapeutics Holdings Cerevel Therapeutics Holdings
CERE
- - $ 7.29 B usaUSA
NexImmune NexImmune
NEXI
- 70.13 % $ 4.12 M usaUSA
Codexis Codexis
CDXS
$ 1.0 -9.91 % $ 87.1 M usaUSA
Theravance Biopharma Theravance Biopharma
TBPH
$ 17.03 0.03 % $ 857 M cayman-islandsCayman-islands
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.06 -3.72 % $ 192 M israelIsrael
IMV IMV
IMV
- - $ 13.1 M canadaCanada
Sanofi Sanofi
SNY
$ 48.23 0.22 % $ 58.9 B franceFrance
Karuna Therapeutics Karuna Therapeutics
KRTX
- - $ 12.2 B usaUSA
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
Atreca Atreca
BCEL
- -11.76 % $ 5.79 M usaUSA
LogicBio Therapeutics LogicBio Therapeutics
LOGC
- - $ 229 M usaUSA
RedHill Biopharma Ltd. RedHill Biopharma Ltd.
RDHL
$ 0.38 -5.06 % $ 4.68 B israelIsrael
89bio 89bio
ETNB
- - $ 1.55 B usaUSA
Fusion Pharmaceuticals Fusion Pharmaceuticals
FUSN
- - $ 1.41 B canadaCanada
Gritstone Oncology Gritstone Oncology
GRTS
- 0.42 % $ 213 M usaUSA
Harpoon Therapeutics Harpoon Therapeutics
HARP
- - $ 763 M usaUSA
HOOKIPA Pharma HOOKIPA Pharma
HOOK
- -6.92 % $ 79.4 M usaUSA
Guardion Health Sciences Guardion Health Sciences
GHSI
- -0.31 % $ 3.64 M usaUSA
Opiant Pharmaceuticals Opiant Pharmaceuticals
OPNT
- - $ 109 M usaUSA
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Otonomy Otonomy
OTIC
- -1.96 % $ 4.68 M usaUSA
Aridis Pharmaceuticals Aridis Pharmaceuticals
ARDS
- 17.91 % $ 11.1 M usaUSA
Seagen Seagen
SGEN
- - $ 42.2 B usaUSA
Protara Therapeutics Protara Therapeutics
TARA
$ 2.44 -2.59 % $ 105 M usaUSA
Baudax Bio Baudax Bio
BXRX
- 0.59 % $ 63 K usaUSA
ChemoCentryx ChemoCentryx
CCXI
- - $ 3.74 B usaUSA
Avid Bioservices Avid Bioservices
CDMO
- - $ 789 M usaUSA
Zosano Pharma Corporation Zosano Pharma Corporation
ZSAN
- 7.23 % $ 2.72 M usaUSA
Oncternal Therapeutics Oncternal Therapeutics
ONCT
- -24.12 % $ 1.56 M usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
- - $ 591 K irlandaIrlanda
Spectrum Pharmaceuticals Spectrum Pharmaceuticals
SPPI
- - $ 189 M usaUSA
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
Alpine Immune Sciences Alpine Immune Sciences
ALPN
- - $ 2.17 B usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
ImmunoGen ImmunoGen
IMGN
- - $ 7.92 B usaUSA
Vascular Biogenics Ltd. Vascular Biogenics Ltd.
VBLT
- -8.77 % $ 12.4 M israelIsrael
Histogen Histogen
HSTO
- 31.6 % $ 2.12 M usaUSA
Berkeley Lights Berkeley Lights
BLI
- -7.31 % $ 87 M usaUSA
Cidara Therapeutics Cidara Therapeutics
CDTX
- - $ 1.41 B usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Kaleido Biosciences Kaleido Biosciences
KLDO
- -3.69 % $ 12.4 M usaUSA
VBI Vaccines VBI Vaccines
VBIV
- -50.87 % $ 1.09 M usaUSA
CTI BioPharma Corp. CTI BioPharma Corp.
CTIC
- - $ 1.2 B usaUSA
Decibel Therapeutics Decibel Therapeutics
DBTX
- - $ 123 M usaUSA
NuCana plc NuCana plc
NCNA
$ 0.94 -2.67 % $ 10.6 B britainBritain
PhaseBio Pharmaceuticals PhaseBio Pharmaceuticals
PHAS
- 7.4 % $ 6.29 M usaUSA
Provention Bio Provention Bio
PRVB
- - $ 2.37 B usaUSA
IVERIC bio IVERIC bio
ISEE
- - $ 5.51 B usaUSA
Reata Pharmaceuticals Reata Pharmaceuticals
RETA
- - $ 6.29 B usaUSA